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Effects of the online computerized cognitive training program BEYNEX on the cognitive
tests of individuals with subjective cognitive impairment and Alzheimer’s disease on
rivastigmine therapy
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Background/aim: Clinical trials conducted on the efficacy of computerized cognitive training (CCT) programs have not led to
any important breakthroughs. CCT is a safe and inexpensive approach, but its efficacy in patients on rivastigmine therapy has not
been evaluated. This study aims to compare effects of CCT and examines rivastigmine to determine whether CCT has any further
contributions to make.
Materials and methods: Sixty individuals with subjective memory complaint (SCI) and 60 individuals with early stage Alzheimer’s
dementia (AD) were subjected to the Montreal Cognitive Assessment (MoCA), Cambridge Cognition (CANTAB tests: MOT, PRM,
DMS, SWM, PAL, RTI), and Bayer-ADL. After screening patients who were diagnosed with AD, we started rivastigmine patch treatment
(10 cm2 = 9.5 mg). The SCI and AD groups were randomly divided, and one each of the SCI and AD groups were accessed using
BEYNEX, a web-based program. After a minimum of at least 1200 min of use, the diagnostic tests were repeated.
Results: The AD groups’ MoCA scores of the BEYNEX-practicing group demonstrated meaningfully increase, whereas they decreased
in the control group, and the Bayer-ADL scores indicated improvement in ADL. The CANTAB tests both in SCI and AD and in groups
using BEYNEX showed positive improvement in MOT, DMS, and PAL data.
Conclusion: This study is a rare example that focuses on both groups with SCI and AD. The efficacy of CCT varies across cognitive
domains and shows significant efficacy for AD but small improvements in cognitively healthy older adults. In future studies, integration
with a smart learning algorithm may lead to interesting observations on which parameters are more sensitive to change under long-term
use of CCT in a large number of subjects.
Key words: Computerized cognitive training, Alzheimer’s disease, subjective cognitive impairment, rivastigmine

1. Introduction
Computer cognitive training (CCT) programs for elderly
people are a relatively new and developing option for
cognitive rehabilitation and continue to be adopted in
many fields of research. CCT is implemented through
group sessions and individual training using a computerbased program modifying protocols previously shown to
be effective in randomized controlled trials [1]. Clinical
trials conducted on the efficacy of CCT have not led
to any important breakthroughs, yet there is a growing
consensus that this can, at least partially, be explained by
methodological difficulties. Although adoption is slow in
clinical research, change is inevitable. Cognitive decline
and memory impairment are a difficult and expensive
aspect of aging [2]. Age-related cognitive impairment rates

affect about 15%–25% of the elderly population, which
makes it nearly twice as common compared to dementia
[3–5]. The health-related costs are nearly 44% higher for
elderly patients with mild cognitive impairment compared
to those who do not have any impairment.
Considering cognitive decline and impairment as the
essential criteria of dementia, it is important to underline
the significant economic and health-related costs of the
caring process and the attempts to prevent or slow down
the decline [6]. There are numerous studies demonstrating
the positive effects of acetylcholinesterase (AChE)
inhibitors on cognitive tests in the first 6 months. All
AChE inhibitors have shown greater efficacy than placebos
in randomized, double-blind, parallel-group clinical trials
[7]. This study observed the effects of CCT on patients
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on rivastigmine, which is also an AChE inhibitor. It also
compared the effects on Alzheimer’s dementia (AD)
patients with a subjective memory complaint (SCI) group,
comprising patients not on any medication. CCT is a safe
and inexpensive approach, but its efficacy in patients on
rivastigmine therapy has not yet been evaluated. This
study aims to compare the effects of CCT and examines
rivastigmine to determine whether CCT has any further
contributions to this effect.
2. Materials and methods
This study was conducted between 1 January and 31
December 2017 at five study sites in İstanbul, Turkey.
Three study sites did not complete the study. Subjects were
recruited in the memory clinics of different hospitals. Out
of 141 individuals aged between 50 and 85 screened for
eligibility, 120 subjects were enrolled in the study.
Exclusion criteria included a history of severe
psychiatric or neurologic disorders, a moderate stage of
dementia changes with antidementive or antidepressive
medication within 3 months prior to study initiation, or
physical conditions that would prevent participation in
the physical training program. The level of education of
subjects was at least secondary school. Depression was
excluded with the Geriatric Depression Scale (GDS),
comprising 30 items, developed by Yesavage to evaluate
depression [8]. Sixty individuals with SCI [9] and 60
individuals with probable AD, as defined by the National
Institute of Neurological and Communicative Disorders
and Stroke/Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria [10], were
subjected to the Montreal Cognitive Assessment (MoCA)
[11] and Cambridge Cognition CANTAB cognitive
assessment software. The CANTAB tests included motor
screening (MOT), pattern recognition memory (PRM),
delayed matching sample (DMS), spatial-working memory
(SWM), paired associated learning (PAL), reaction time
(RTI) [12], and Bayer-ADL tests [13]. We accepted SCI
patients as individuals who reported a worsening of their
thinking abilities, including memory, but for whom the
decline could not be verified by standard tests [9].
After screening patients who were diagnosed with
AD, rivastigmine patch treatment (10 cm2 = 9.5 mg) was
started. Later, the SCI and AD groups’ age and education
levels were normalized and divided into two subgroups
consisting of 30 subjects. The SCI and AD subgroups were
provided a password to access the web-based BEYNEX
program and were asked to complete tasks, which included
playing 3 different 5-min-long computer games, practicing
a 3-min-long physical exercise video on a daily basis, and
answering questions on Bayer-ADL once a week (Figure
1). All tasks were designed within the parameters used
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by clinicians and took 15–20 min to complete daily. The
BEYNEX exercises are completely unique and are not in
commercial use, and the initial research outcomes were
presented at the Alzheimer’s Association International
Conference (AAIC 2018/Technology and Dementia,
Chicago, IL, USA) [14]. Patients’ total activity time (Figure
2), Bayer-ADL scores, and game performances were
monitored only by clinicians using 9 different parameters
(ADL, Memory, Visual Perception, Speed, ProblemSolving, Flexibility, Attention, Language Skills, Arithmetic)
(Figure 3). After 3 months or at least 1200 min of BEYNEX
use, the diagnostic tests (MoCA, CANTAB, B-ADL) were
repeated for both test and control groups.
SPSS 16.0 (SPSS Inc., Chicago, IL, USA) was used
for statistical analyses. Statistical analysis was performed
using one-way ANOVA test with post hoc analysis using
the Tukey test.
3. Results
All subjects’ routine laboratory test results were within
normal limits, including complete blood cell count, serum
electrolyte levels including magnesium and glucose,
serum chemistry panel (BUN/creatinine), liver function
tests, thyroid function tests, and serum vitamin B12 tests.
One hundred and forty-one participants were enrolled in
the intervention study. Due to dropouts, the data of 120
subjects were analyzed with a mean age of 70.52 years (SD:
8.77 years, range: 50–85 years), whom had been allocated
to 4 different groups, each consisting of 30 subjects (SCI,
SCI+BEYNEX, AD, AD+BEYNEX).
The SCI and AD groups’ cognitive performances
were analyzed separately, and the SCI and AD groups
did not differ significantly in terms of sociodemographic
variables or baseline lifestyle activity (Table 1). Among the
SCI groups, no meaningful differences were determined
between the beginning and the results of the MoCA,
GDS, and B-ADL scales (Table 2), whereas the CANTAB
results indicated statistically meaningful changes (Table
3). The results of the exercise-practicing group showed
positive improvement in parameters of MOT (median),
DMS [percent correct and percent correct (all delays)],
PAL [total errors (adjusted) and total errors (6 shapes,
adjusted)]. The PRM, SWM, and RTI parameters showed
no change (Table 3). The AD groups exhibited meaningful
differences between the initial and final MoCA, B-ADL,
and CANTAB scores. The final MoCA scores of the
BEYNEX-practicing group demonstrated a meaningful
increase, whereas they decreased in the AD control group.
The final B-ADL scores of the BEYNEX-practicing groups
meaningfully decreased, indicating an improvement
in ADL (Table 2). The CANTAB scores of the BEYNEX
groups showed improvement in the parameters of motor
screening (MOT), delayed matching sample (DMS),
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Did you have spare time for reading yesterday?

Did you have a phone conversation yesterday?

Figure 1. Questions of daily living activities (2 examples of 25 questions).

Figure 2. Patient total performance screen.

paired associated learning (PAL), pattern recognition
memory (PRM), and spatial-working memory (SWM).
The reaction time (RTI) parameters showed no change
(Table 4).

4. Discussion
The efficacy of CTT on cognition is a highly debated subject
in the medical literature. The cognitive states of individuals
and their changes are generally determined by quick scans
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Figure 3. Patient performance screen for 8 different parameters (Memory, Visual Perception, Speed, Problem-Solving, Flexibility,
Attention, Language Skills, Arithmetic).

(e.g., MoCA, MMSE) or other scales. Particularly for
individuals with SCI diagnosis, these scales do not signal
the change strongly enough. Similarly, our study on MoCA
scale CCT showed no changes in the SCI group, whereas
in the AD group CCT indicated significant efficacy. Hence,
the study included CANTAB to enrich the measurement
of cognitive parameters.
In our study, the CANTAB tests for both SCI and AD
groups showed significant differences in MOT, DMS, and
PAL data. The motor screening test (MOT) is a training
procedure designed to relax subjects and to introduce
them to the computer and touch screen. It simultaneously
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screens for difficulties with vision, movement, and
comprehension, and it ascertains whether the subject can
follow simple instructions, as well as familiarizing them
with the touch screen. The DMS is a test of simultaneous
and delayed matching-to-sample. This test is primarily
sensitive to damage in the medial temporal lobe area, with
some input from the frontal lobes. The paired associates
learning (PAL) test assesses visual episodic recall memory
and new learning, and it is sensitive to medial temporal
lobe dysfunction [15]. The spatial working memory
(SWM) test is an instrument for assessment of working
memory. It is a test of the subject’s ability to retain spatial
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Table 1. The demographic and lifestyle characteristics within four intervention groups.
Variable

SCI

SCI/BEYNEX

AD

AD/BEYNEX

Age: M (SD)

68.3 (10.94)

66.5 (9.79)

70.85 (7.78)

74.3 (7.56)

Sex: male/female

10/20

13/17

16/14

14/16

Education in years, M (SD)

11.57 (4.42)

13.27(3.66)

11.63 (3.99)

7.83 (3.99)

BMI

29.26 (9.04)

27.46 (4.31)

27.45 (3.21)

28.29 (4.45)

HT

15/30

18/30

19/30

19/30

Exercise

8/30

20/30

21/30

14/30

Smoking

14/30

20/30

16/30

14/30

Alcohol consumption

7/30

10/30

7/30

5/30

Depicted are means (M) and standard deviations (SD) in parentheses. SCI= Subjective cognitive impairment;
AD= Alzheimer dementia; BMI= body mass index; HT= hypertension.

Table 2. The Cognitive, psychiatric, and activity of daily living assessments.
Variable

Assessment

SCI

SCI/BEYNEX

AD

AD/BEYNEX

MoCA: M (SD)

1st assessment

23.5 (2.91)

24.1 (2.92)

19.07 (2.61)

20.83 (3.39) ***

2nd assessment

22.03 (5.24)

26.13 (2.87)

16.27 (3.94)

23.23 (3.68) ***

1st assessment

2.60 (1.46)

2.54 (1.63)

3.54 (1.84)

4.62 (1.89)***

2nd assessment

2.99 (1.81)

2.42 (1.73)

3.20 (1.66)

3.97 (1.93)***

1st assessment

8.33 (4.50)

5.97 (3.31)

5.07 (2.85)

5.57 (3.02)

2nd assessment

6.70 (1.96)

4.17 (2.77)

3.77 (3.04)

4.70 (2.94)

Bayer-ADL (SD)
GDS (SD)

SCI and AD subgroups were analyzed separately. Depicted are means (M) and standard deviations (SD) in parentheses.
Statistical analysis was performed using one-way ANOVA test; ***P < 0.001.
SCI= Subjective cognitive impairment; AD= Alzheimer dementia; MoCA= Montreal Cognitive Assessment; B-ADL=
Bayer Activities of Daily Living.

information and to manipulate remembered items in
the working memory. The self-ordered task, which also
assesses heuristic strategy, is a sensitive measure of frontal
lobe and “executive” dysfunction. The PRM is a test of
visual pattern recognition memory in a two-choice forced
discrimination paradigm and is sensitive to dysfunction
in the medial temporal areas of the brain and relatively
insensitive to dysfunction in the frontal lobe. The RTI is
designed to measure the subject’s speed of response to
a visual target, where the stimulus is either predictable
(simple reaction time) or unpredictable (choice reaction
time) [15].
The B-ADL has been developed on an international
basis to assess deficits in the performance of everyday
activities. The scales mainly target patients suffering mild
cognitive impairment or mild-to-moderate dementia. It
comprises 25 items and takes the form of a questionnaire to

be completed by a caregiver or other informant sufficiently
familiar with the patient. The scale uses items that reflect
a wide range of domains. It is suitable for both screening
patients’ ADL capacities and documentation of treatment
effects and the progress of dementia [13]. BEYNEX requires
users to answer 25 questions once a week about their daily
activities. These questions are designed to include activities
evaluated by B-ADL. The patients are motivated to be more
active by these weekly questions, and the responses (“Yes/
No/Not Applicable”) are plotted in a time-series graph for
medical professionals to monitor. There are significantly
meaningful differences observed on this scale, particularly
in patients who are sensitive to cognitive change due to
rivastigmine therapy in the AD group. Periodic monitoring
of daily activities in an online environment does motivate
patients with early-stage AD to adopt a more active lifestyle.
The GDS, comprising 30 items, was developed by Yesavage
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Table 3. CANTAB test results of SCI groups comparing pre and post CCT (Beynex)
Mean

Std.
Deviation

Lower
Bound

Upper
Bound

F

p-Value

MOTmean

836.62

216.88

797.42

875.82

2.45

0.067

MOTMedian

802.99

215.76

763.99

841.99

3.07

0.031*

PRM

78.51

13.35

76.09

80.92

1.07

0.365

DMSA

75.24

14.08

72.70

77.79

3.79

0.012*

DMSB

89.64

14.18

87.08

92.20

2.15

0.097

DMSC

70.45

15.90

67.58

73.33

3.44

0.019

PALA

62.39

54.10

52.61

72.17

4.57

0.005**

PALB

17.58

17.59

14.40

20.75

3.42

0.02*

SWMA

48.63

22.01

44.65

52.60

0.72

0.544

SWMB

34.58

9.88

32.80

36.37

1.06

0.368

SimpleRTIA

8.55

1.08

8.35

8.74

0.36

0.782

SimpleRTIB

405.72

130.98

381.84

429.60

0.90

0.446

SimpleRTIC

374.20

92.47

357.34

391.06

0.89

0.447

SimpleRTID

599.17

182.95

565.81

632.52

1.16

0.328

SimpleRTIE

571.24

158.55

542.33

600.14

1.05

0.373

FiveRTIA

7.87

0.86

7.71

8.02

0.98

0.406

FiveRTIB

435.60

117.91

414.10

457.10

0.44

0.728

FiveRTIC

413.28

98.87

395.25

431.30

0.22

0.881

FiveRTID

565.95

164.02

535.92

595.99

0.74

0.531

FiveRTIE

560.53

146.69

533.55

587.51

0.59

0.625

Statistical analysis was performed using one-way ANOVA test; p<.05 *; p<.01 **

to evaluate depression. Though it showed small changes in
the SCI and AD groups, the results are not meaningful.
These findings suggest that CCT produces small
improvements in cognitive performance in cognitively
healthy older adults but that the efficacy of CCT varies
across cognitive domains and is largely determined by the
design aspects of CCT. Moreover, because all the included
studies measured cognitive function immediately after
CCT, these findings provide no information about the
durability of the effects of CCT or how the effects of CCT
on cognitive function translate into real-life outcomes
for individuals such as independence and the long-term
risk of dementia. Monitoring the user’s performance over
long periods via online software such as BEYNEX can be
utilized as a flagging tool for early-stage AD diagnosis,
even though it would be difficult to establish a full
diagnosis [14].
This study is a rare example of a study that focuses on
groups with both SCI and AD. In line with the existing
literature, it reiterates that the efficacy of CCT is negligible
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on SCI patients [16–18]. However, the results also suggest
that CCT is more efficient in long-term use (at least 6
months), as well as when it is more accessible online rather
than via on-site training. It is important for subjects to
integrate CCT into their daily-life routines [19]. In future
studies, for systems like BEYNEX, integration with a
smart learning algorithm (modest examples of artificial
intelligence) may lead to interesting observations in which
parameters are more sensitive to change under long-term
use of
CCT in a large number of subjects. There is thus a
need for additional research on CCT, an intervention that
might help to attenuate age-related cognitive decline and
improve the quality of life for older individuals.
In conclusion, this study is a rare example that focuses
on both groups with SCI and AD. In line with the existing
literature, it reiterates that the efficacy of CCT is negligible
in SCI patients but it shows significant efficacy for AD
patients. It is important for patients to integrate CCT into
their daily-life routines.
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Table 4. The CANTAB test results of AD groups comparing pre- and post-CCT results (BEYNEX).
Mean

Std.
deviation

Lower
bound

Upper
bound

F

P-value

MOTmean

1130.20

404.63

1057.08

1203.36

6.35

0.001**

MOTMedian

1037.00

360.63

971.78

1102.16

5.73

0.001**

PRM

64.77

16.74

61.75

67.80

10.18

0.001**

DMSA

60.47

17.31

57.34

63.60

7.10

0.001**

DMSB

78.31

22.58

74.22

82.39

9.76

0.001**

DMSC

54.65

18.16

51.37

57.93

4.22

0.01**

PALA

123.64

68.20

111.31

135.97

5.24

0.001**

PALB

35.10

19.03

31.66

38.54

3.39

0.02**

SWMA

54.72

34.99

48.39

61.04

0.98

0.40

SWMB

30.14

15.87

27.27

33.01

6.07

0.001**

SimpleRTIA

8.16

5.38

7.18

9.15

0.28

0.84

SimpleRTIB

525.62

230.18

481.71

569.53

0.76

0.52

SimpleRTIC

476.69

212.91

436.07

517.30

0.46

0.71

SimpleRTID

849.82

377.85

777.40

922.24

0.47

0.70

SimpleRTIE

791.59

373.11

720.08

863.10

0.69

0.56

FiveRTIA

12.19

49.69

2.75

21.62

1.37

0.26

FiveRTIB

545.76

207.39

502.81

588.71

0.88

0.45

FiveRTIC

505.92

192.11

466.13

545.70

0.69

0.56

FiveRTID

714.59

234.79

665.96

763.21

0.38

0.77

FiveRTIE

688.01

202.59

646.05

729.96

0.22

0.88

Statistical analysis was performed using one-way ANOVA test; *P < 0.05; **P < 0.01; ***P < 0.001.
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